NCT03624231
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03624231 |
| Title | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD) |
| Acronym | DURTRE-RAD |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Ulrich Keilholz |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | DEU |
CKB BOOST